Investor Presentaiton

BIOND BIOLOGICS • ° BND-35 Target Product Profile Product Description Ig-Like Transcript 3 (ILT3) receptor antagonist antibody Strategic Context / Differentiation Checkpoint inhibitor targeting immuno- supresisve cells in the TME ILT3 is a new, emerging target in cancer immunotherapy }: Scientific Rationale Suppressive myeloid cells in the tumor microenvironment (TME) limit the potency of therapeutic interventions ILT3 is expressed by suppressive myeloid cells in cancer patients and has a key role in the activity of these cells ILT3 inhibits the effector activity of T cells and enhances the suppressive activity of myeloid cells MOA/Clinical Pharmacology BND-35 is an antibody that binds to the ILT3 receptor and disrupts its interaction with its T cell ligand, Releases ILT3 mediated immuno-supression in the TME to enable efficient anti-tumor immune activity Indication(s) and patient 3 population • Solid tumors known to have a highly suppressive tumor microenvironment 目 # Stage Pre-clinic Patients with unresectable or metastatic disease, with disease progression following prior systemic therapies including PD(L)-1 blockers Biond Biologics Corporate Presentation | May 2021 | Non-confidential 31

View entire presentation